CM-101-treated patients demonstrated moderate improvements in their fibrosis biomarkers, including serum ProC3 and TIMP1 levels (serum markers of ECM synthesis and turnover) and the enhanced liver fibrosis score (composite score based on the levels of circulating hyaluronic acid, procollagen III amino-terminal peptide (PIIINP), and TIMP1). Here, TIMP1 is linked to Hepatic fibrosis.